{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T10:26:25Z","timestamp":1791282385790,"version":"4.1.0"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:00:00Z","timestamp":1667952000000},"content-version":"vor","delay-in-days":2718,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1111\/jth.12947","type":"journal-article","created":{"date-parts":[[2015,6,21]],"date-time":"2015-06-21T08:15:36Z","timestamp":1434874536000},"page":"S313-S322","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"special_numbering":"S1","title":["Antiplatelet drugs: which targets for which treatments?"],"prefix":"10.1016","volume":"13","author":[{"given":"C.","family":"Gachet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/jth.12947_bb0010","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1161\/CIRCULATIONAHA.110.963843","article-title":"Aspirin: a historical and contemporary therapeutic overview","volume":"123","author":"Fuster","year":"2011","journal-title":"Circulation"},{"key":"10.1111\/jth.12947_bb0015","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1055\/s-2005-869523","article-title":"Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate\u2010receptor antagonists for the prevention of atherothrombosis","volume":"31","author":"Savi","year":"2005","journal-title":"Semin Thromb Hemost"},{"key":"10.1111\/jth.12947_bb0020","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1146\/annurev.pharmtox.46.120604.141207","article-title":"Regulation of platelet functions by P2 receptors","volume":"46","author":"Gachet","year":"2006","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1111\/jth.12947_bb0025","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1182\/blood-2008-06-077891","article-title":"The GPIIb\/IIIa (integrin alphaIIbbeta3) odyssey: a technology\u2010driven saga of a receptor with twists, turns, and even a bend","volume":"112","author":"Coller","year":"2008","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1111\/jth.12947_bb0030","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/jth.12235","article-title":"Platelet receptors activated via mulitmerization: glycoprotein VI, GPIb\u2010IX\u2010V, and CLEC\u20102","volume":"11","author":"Ozaki","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.12947_bb0035","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1161\/01.RES.0000251742.71301.16","article-title":"Activation of platelet function through G protein\u2010coupled receptors","volume":"99","author":"Offermanns","year":"2006","journal-title":"Circ Res"},{"issue":"Suppl. 1","key":"10.1111\/jth.12947_bb0040","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/j.1538-7836.2011.04356.x","article-title":"Historical perspective and future directions in platelet research","volume":"9","author":"Coller","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.12947_bb0045","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ahj.2014.06.014","article-title":"Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold?","volume":"168","author":"Huber","year":"2014","journal-title":"Am Heart J"},{"key":"10.1111\/jth.12947_bb0050","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1146\/annurev-pharmtox-010814-124438","article-title":"New approaches to inhibiting platelets and coagulation","volume":"55","author":"Depta","year":"2015","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1111\/jth.12947_bb0055","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nrcardio.2014.156","article-title":"Novel antiplatelet agents in acute coronary syndrome","volume":"12","author":"Franchi","year":"2015","journal-title":"Nat Rev Cardiol"},{"key":"10.1111\/jth.12947_bb0060","doi-asserted-by":"crossref","first-page":"e247","DOI":"10.1016\/j.ijcard.2013.12.103","article-title":"Prevalence, clinical profile and 3\u2010year survival of acute myocardial infarction patients with and without obstructive coronary lesions: the FAST\u2010MI 2005 registry","volume":"172","author":"Andre","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1111\/jth.12947_bb0065","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1161\/STROKEAHA.107.496729","article-title":"Trends in usage of alternative antiplatelet therapy after stroke and transient ischemic attack","volume":"39","author":"Hills","year":"2008","journal-title":"Stroke"},{"key":"10.1111\/jth.12947_bb0070","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1001\/jama.2013.1490","article-title":"Antiplatelet therapy to prevent cardiovascular events and mortality in patients with intermittent claudication","volume":"309","author":"Wong","year":"2013","journal-title":"JAMA"},{"key":"10.1111\/jth.12947_bb0075","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1182\/blood-2011-06-359224","article-title":"Aspirin\u2010insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target","volume":"119","author":"Pascale","year":"2012","journal-title":"Blood"},{"key":"10.1111\/jth.12947_bb0080","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1111\/j.1538-7836.2012.04723.x","article-title":"The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low\u2010dose aspirin in patients with and without diabetes","volume":"10","author":"Rocca","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.12947_bb0085","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta\u2010analysis of individual participant data from randomised trials","volume":"373","author":"Baigent","year":"2009","journal-title":"Lancet"},{"key":"10.1111\/jth.12947_bb0090","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta\u2010analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","year":"2002","journal-title":"BMJ"},{"key":"10.1111\/jth.12947_bb0095","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1001\/jama.2014.16047","article-title":"When should aspirin be used for prevention of cardiovascular events?","volume":"312","author":"Gaziano","year":"2014","journal-title":"JAMA"},{"key":"10.1111\/jth.12947_bb0100","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(97)04011-7","article-title":"The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group","volume":"349","year":"1997","journal-title":"Lancet"},{"key":"10.1111\/jth.12947_bb0105","doi-asserted-by":"crossref","first-page":"e601S","DOI":"10.1378\/chest.11-2302","article-title":"Antithrombotic and thrombolytic therapy for ischemic stroke: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence\u2010Based Clinical Practice Guidelines","volume":"141","author":"Lansberg","year":"2012","journal-title":"Chest"},{"key":"10.1111\/jth.12947_bb0110","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000369778","article-title":"Aspirin plus clopidogrel as secondary prevention after stroke or transient ischemic attack: a systematic review and meta\u2010analysis","volume":"39","author":"Zhang","year":"2014","journal-title":"Cerebrovasc Dis"},{"key":"10.1111\/jth.12947_bb0115","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(04)16721-4","article-title":"Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high\u2010risk patients (MATCH): randomised, double\u2010blind, placebo\u2010controlled trial","volume":"364","author":"Diener","year":"2004","journal-title":"Lancet"},{"key":"10.1111\/jth.12947_bb0120","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/978-3-642-29423-5_11","article-title":"Thromboxane receptors antagonists and\/or synthase inhibitors","volume":"210","author":"Davi","year":"2012","journal-title":"Handb Exp Pharmacol"},{"key":"10.1111\/jth.12947_bb0125","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/S0140-6736(11)60600-4","article-title":"Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double\u2010blind, parallel\u2010group trial","volume":"377","author":"Bousser","year":"2011","journal-title":"Lancet"},{"key":"10.1111\/jth.12947_bb0130","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.ehj.2004.07.013","article-title":"Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2\u2010year mortality in diabetics with peripheral arterial disease: the DAVID study","volume":"25","author":"Neri","year":"2004","journal-title":"Eur Heart J"},{"key":"10.1111\/jth.12947_bb0135","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/35051599","article-title":"Identification of the platelet ADP receptor targeted by antithrombotic drugs","volume":"409","author":"Hollopeter","year":"2001","journal-title":"Nature"},{"key":"10.1111\/jth.12947_bb0140","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s11302-012-9303-x","article-title":"P2Y(12) receptors in platelets and other hematopoietic and non\u2010hematopoietic cells","volume":"8","author":"Gachet","year":"2012","journal-title":"Purinergic Signal"},{"key":"10.1111\/jth.12947_bb0145","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1111\/j.1538-7836.2008.03136.x","article-title":"Interaction of the active metabolite of prasugrel, R\u2010138727, with cysteine 97 and cysteine 175 of the human P2Y12 receptor","volume":"6","author":"Algaier","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.12947_bb0150","doi-asserted-by":"crossref","first-page":"11069","DOI":"10.1073\/pnas.0510446103","article-title":"The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts","volume":"103","author":"Savi","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1111\/jth.12947_bb0155","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1161\/CIRCULATIONAHA.109.853069","article-title":"New P2Y(12) inhibitors","volume":"121","author":"Cattaneo","year":"2010","journal-title":"Circulation"},{"key":"10.1111\/jth.12947_bb0160","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1182\/blood-2010-08-263111","article-title":"The platelet P2Y receptor for adenosine diphosphate: congenital and drug\u2010induced defects","volume":"117","author":"Cattaneo","year":"2011","journal-title":"Blood"},{"key":"10.1111\/jth.12947_bb0165","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1111\/j.1538-7836.2009.03527.x","article-title":"Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP\u2010induced receptor signaling and platelet aggregation","volume":"7","author":"van Giezen","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.12947_bb0170","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1111\/jth.12719","article-title":"Competitive mode and site of interaction of ticagrelor at the human platelet P2Y12 \u2010receptor","volume":"12","author":"Hoffmann","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.12947_bb0175","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/nature13288","article-title":"Agonist\u2010bound structure of the human P2Y12 receptor","volume":"509","author":"Zhang","year":"2014","journal-title":"Nature"},{"key":"10.1111\/jth.12947_bb0180","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nature13083","article-title":"Structure of the human P2Y12 receptor in complex with an antithrombotic drug","volume":"509","author":"Zhang","year":"2014","journal-title":"Nature"},{"key":"10.1111\/jth.12947_bb0185","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nm1232","article-title":"PI 3\u2010kinase p110beta: a new target for antithrombotic therapy","volume":"11","author":"Jackson","year":"2005","journal-title":"Nat Med"},{"key":"10.1111\/jth.12947_bb0190","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1161\/01.ATV.19.8.2007","article-title":"Specific impairment of human platelet P2Y(AC) ADP receptor\u2010mediated signaling by the antiplatelet drug clopidogrel","volume":"19","author":"Geiger","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1111\/jth.12947_bb0195","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1538-7836.2004.01063.x","article-title":"Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases","volume":"3","author":"Aleil","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.12947_bb0200","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee","volume":"348","author":"Committee","year":"1996","journal-title":"Lancet"},{"key":"10.1111\/jth.12947_bb0205","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","article-title":"Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events","volume":"354","author":"Bhatt","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.12947_bb0210","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.12947_bb0215","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1056\/NEJMp0806848","article-title":"Prasugrel in clinical practice","volume":"361","author":"Bhatt","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.12947_bb0220","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/j.jacc.2014.03.031","article-title":"Adenosine\u2010mediated effects of ticagrelor: evidence and potential clinical relevance","volume":"63","author":"Cattaneo","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/jth.12947_bb0225","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.12947_bb0230","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1056\/NEJMoa1300815","article-title":"Effect of platelet inhibition with cangrelor during PCI on ischemic events","volume":"368","author":"Bhatt","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.12947_bb0235","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1161\/STROKEAHA.107.508853","article-title":"Ab E\u2010III. Treating patients with \u2018wake\u2010up\u2019 stroke: the experience of the AbESTT\u2010II trial","volume":"39","author":"Adams","year":"2008","journal-title":"Stroke"},{"key":"10.1111\/jth.12947_bb0240","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1161\/01.CIR.0000019581.22812.B2","article-title":"Platelet glycoprotein IIb\/IIIa inhibitors: recognition of a two\u2010edged sword?","volume":"106","author":"Quinn","year":"2002","journal-title":"Circulation"},{"key":"10.1111\/jth.12947_bb0245","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1160\/TH11-10-0727","article-title":"GPIIb\/IIIa inhibitors: from bench to bedside and back to bench again","volume":"107","author":"Armstrong","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.12947_bb0250","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1161\/ATVBAHA.114.303724","article-title":"RUC\u20104: a novel alphaIIbbeta3 antagonist for prehospital therapy of myocardial infarction","volume":"34","author":"Li","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1111\/jth.12947_bb0255","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1055\/s-0032-1326785","article-title":"Diagnosis and management of high platelet reactivity on treatment with clopidogrel","volume":"38","author":"Cattaneo","year":"2012","journal-title":"Semin Thromb Hemost"},{"key":"10.1111\/jth.12947_bb0260","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1160\/TH12-08-0588","article-title":"High on\u2010treatment platelet reactivity and P2Y12 antagonists in clinical trials","volume":"109","author":"Trenk","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.12947_bb0265","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1182\/blood-2014-01-512723","article-title":"Role of phenotypic and genetic testing in managing clopidogrel therapy","volume":"124","author":"Chan","year":"2014","journal-title":"Blood"},{"key":"10.1111\/jth.12947_bb0270","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30\u00a0months of dual antiplatelet therapy after drug\u2010eluting stents","volume":"371","author":"Mauri","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.12947_bb0275","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jjcc.2014.10.006","article-title":"Antiplatelet therapy after drug\u2010eluting stent implantation","volume":"65","author":"Warren","year":"2015","journal-title":"J Cardiol"},{"key":"10.1111\/jth.12947_bb0280","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1111\/j.1538-7836.2005.01377.x","article-title":"Protease\u2010activated receptors in hemostasis, thrombosis and vascular biology","volume":"3","author":"Coughlin","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.12947_bb0285","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1056\/NEJMoa1200933","article-title":"Vorapaxar in the secondary prevention of atherothrombotic events","volume":"366","author":"Morrow","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.12947_bb0290","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1109719","article-title":"Thrombin\u2010receptor antagonist vorapaxar in acute coronary syndromes","volume":"366","author":"Tricoci","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.12947_bb0295","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.tips.2012.07.004","article-title":"Platelet GPVI: a target for antithrombotic therapy?!","volume":"33","author":"Dutting","year":"2012","journal-title":"Trends Pharmacol Sci"},{"key":"10.1111\/jth.12947_bb0300","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1111\/jth.12009","article-title":"The future of glycoprotein VI as an antithrombotic target","volume":"10","author":"Zahid","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.12947_bb0305","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.1182\/blood-2005-09-3687","article-title":"Glycoprotein VI\u2010dependent and \u2010independent pathways of thrombus formation in\u00a0vivo","volume":"107","author":"Dubois","year":"2006","journal-title":"Blood"},{"key":"10.1111\/jth.12947_bb0310","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1538-7836.2009.03666.x","article-title":"Arterial thrombosis: relevance of a model with two levels of severity assessed by histologic, ultrastructural and functional characterization","volume":"8","author":"Hechler","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.12947_bb0315","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1124\/jpet.111.189050","article-title":"A humanized glycoprotein VI (GPVI) mouse model to assess the antithrombotic efficacies of anti\u2010GPVI agents","volume":"341","author":"Mangin","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1111\/jth.12947_bb0320","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1096\/fj.03-0464fje","article-title":"Soluble glycoprotein VI dimer inhibits platelet adhesion and aggregation to the injured vessel wall in\u00a0vivo","volume":"18","author":"Massberg","year":"2004","journal-title":"FASEB J"},{"key":"10.1111\/jth.12947_bb0325","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1160\/TH06-05-0266","article-title":"Ex vivo evaluation of anti\u2010GPVI antibody in cynomolgus monkeys: dissociation between anti\u2010platelet aggregatory effect and bleeding time","volume":"96","author":"Matsumoto","year":"2006","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.12947_bb0330","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1161\/CIRCULATIONAHA.107.691279","article-title":"Targeting platelets in acute experimental stroke: impact of glycoprotein Ib, VI, and IIb\/IIIa blockade on infarct size, functional outcome, and intracranial bleeding","volume":"115","author":"Kleinschnitz","year":"2007","journal-title":"Circulation"},{"key":"10.1111\/jth.12947_bb0335","doi-asserted-by":"crossref","first-page":"e66960","DOI":"10.1371\/journal.pone.0066960","article-title":"The GPVI\u2010Fc fusion protein Revacept improves cerebral infarct volume and functional outcome in stroke","volume":"8","author":"Goebel","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1111\/jth.12947_bb0340","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1161\/CIRCULATIONAHA.110.980623","article-title":"Novel antiplatelet drug revacept (dimeric glycoprotein VI\u2010Fc) specifically and efficiently inhibited collagen\u2010induced platelet aggregation without affecting general hemostasis in humans","volume":"123","author":"Ungerer","year":"2011","journal-title":"Circulation"},{"key":"10.1111\/jth.12947_bb0345","doi-asserted-by":"crossref","first-page":"e101209","DOI":"10.1371\/journal.pone.0101209","article-title":"Discovery of novel GPVI receptor antagonists by structure\u2010based repurposing","volume":"9","author":"Taylor","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1111\/jth.12947_bb0350","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1750-1172-1-46","article-title":"Bernard\u2010Soulier syndrome (hemorrhagiparous thrombocytic dystrophy)","volume":"1","author":"Lanza","year":"2006","journal-title":"Orphanet J Rare Dis"},{"key":"10.1111\/jth.12947_bb0355","article-title":"Interaction of von Willebrand\u00a0factor with platelets and the vessel wall","volume":"35","author":"Ruggeri","year":"2015","journal-title":"Hamostaseologie"},{"key":"10.1111\/jth.12947_bb0360","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1182\/blood-2013-12-543074","article-title":"GpIbalpha\u2010VWF blockade restores vessel patency by dissolving platelet aggregates formed under very high shear rate in mice","volume":"123","author":"Le Behot","year":"2014","journal-title":"Blood"},{"key":"10.1111\/jth.12947_bb0365","doi-asserted-by":"crossref","first-page":"5088","DOI":"10.1182\/blood-2012-11-464545","article-title":"Reperfusion of cerebral artery thrombosis by the GPIb\u2010VWF blockade with the Nanobody ALX\u20100081 reduces brain infarct size in guinea pigs","volume":"121","author":"Momi","year":"2013","journal-title":"Blood"},{"key":"10.1111\/jth.12947_bb0370","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/ajh.23106","article-title":"Initial experience from a double\u2010blind, placebo\u2010controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura","volume":"87","author":"Cataland","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1111\/jth.12947_bb0375","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/978-3-642-29423-5_12","article-title":"Inhibitors of the interaction between von Willebrand factor and platelet GPIb\/IX\/V","volume":"210","author":"Gresele","year":"2012","journal-title":"Handb Exp Pharmacol"},{"key":"10.1111\/jth.12947_bb0380","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1160\/TH11-12-0889","article-title":"The anti\u2010von Willebrand factor aptamer ARC1779 increases von Willebrand factor levels and platelet counts in patients with type 2B von Willebrand disease","volume":"108","author":"Jilma\u2010Stohlawetz","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.12947_bb0385","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1161\/STROKEAHA.111.616649","article-title":"The von Willebrand inhibitor ARC1779 reduces cerebral embolization after carotid endarterectomy: a randomized trial","volume":"42","author":"Markus","year":"2011","journal-title":"Stroke"},{"key":"10.1111\/jth.12947_bb0390","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1053\/j.seminhematol.2014.03.004","article-title":"Direct oral anticoagulants in acute coronary syndrome","volume":"51","author":"Ahrens","year":"2014","journal-title":"Semin Hematol"},{"key":"10.1111\/jth.12947_bb0395","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jacc.2013.03.041","article-title":"Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS\u2010ACS 2 TIMI 51","volume":"62","author":"Gibson","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjth.12947","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjth.12947","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622042404?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622042404?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jth.12947\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:13:32Z","timestamp":1761534812000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622042404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":78,"alternative-id":["S1538783622042404"],"URL":"https:\/\/doi.org\/10.1111\/jth.12947","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiplatelet drugs: which targets for which treatments?","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.12947","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}